Sugi Predict

Sugi Predict / Compounds / SCHEMBL3024877

SCHEMBL3024877

SCHEMBL3024877

NC(=O)c1c(F)cc(Cl)cc1F

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 3/20 0.42
▸ MAP2 P11137 1/20 0.41
▸ SPR P35270 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ PARP1 P09874 2/20 0.39
▸ LMNA P02545 1/20 0.37
▸ APP P05067 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ DGAT1 O75907 1/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ TPMT P51580 1/20 0.36
▸ PBRM1 Q86U86 1/20 0.36
▸ GAA P10253 1/20 0.34
▸ HRH4 Q9H3N8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046581 0.89 GRM2 (0.40) GRM2MAP2SPRPOLBPARP1
SCHEMBL3023635 0.87 SPR (0.46) GRM2MAP2SPRPOLBPARP1
SCHEMBL1398127 0.87 CYP3A4 (0.41) GRM2MAP2SPRPOLBPARP1
SCHEMBL5952491 0.86 POLB (0.50) GRM2MAP2POLBLMNAAPP
SCHEMBL31140501 0.86 DGAT1 (0.39) GRM2MAP2SPRPOLBPARP1
SCHEMBL26486063 0.81 MAP2K1 (0.43) MAP2POLBLMNAGAA
SCHEMBL1003390 0.80 CES2 (0.44) SPRPARP1DGAT1GAA
SCHEMBL811633 0.78 PARP1 (0.45) POLBPARP1DGAT1
SCHEMBL4262805 0.78 DGAT1 (0.38) POLBPARP1DGAT1IDO1PBRM1
Hydrochloric Acid SCHEMBL29810617 0.78 CES2 (0.43) SPRPARP1DGAT1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US claimed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US claimed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP claimed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO claimed
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 — — US disclosed
CN-119528824-A 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2025-02-28 — — CN disclosed
CN-113166078-B 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2024-11-19 — — CN disclosed
WO-2023066283-A1 METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-04-27 — — WO disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 — — US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 — — EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 — — US disclosed
US-20100204218-A1 FUSED BICYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-08-12 — — US disclosed
EP-2179994-A1 FUSED BICYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-28 — — EP disclosed
EP-2179994-A1 FUSED BICYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-28 — — EP disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 GRM2 4620/4885MAP2 1178/4885SPR 4038/4885
US-20100204218-A1 FUSED BICYCLIC COMPOUND NR3C2, NR3C1, MC2R GRM2 122/4885MAP2 1227/4885SPR 621/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A GRM2 4548/4885MAP2 1267/4885SPR 4328/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A GRM2 345/4885MAP2 621/4885SPR 2413/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A GRM2 345/4885MAP2 621/4885SPR 2413/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A GRM2 345/4885MAP2 621/4885SPR 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.